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Abstract 
 This work is focused on the application of simple biochemical 
techniques to study protein-ligand interaction involved in some diseases 
of frequent incidence, such as Alzheimer’s disease (AD) and cancer.  
 The current therapies for AD, still symptomatic and palliative, 
from one side act to inhibit AChE, in order to restore the natural level of 
ACh, and, from the other side act as inhibitors of β-secretase 1 (BACE-1), 
useful to prevent the Aβ aggregation. Under this regard, efforts have been 
recently devoted to the development of dual inhibitors of AChE and 
BACE-1. 
 In this frame, donepezil-like compounds were synthesised, in 
order to identify novel effective drugs for the treatment of AD. For all 
these new synthesized analogues, more rigid and diversely substituted 
compared to donepezil structure, the inhibitor activity on AChE, the 
selectivity vs BuChE, the side-activity on BACE-1 and the effect on 
SHSY-5Y neuroblastoma cell viability were tested. Two potential new 
lead compounds for a dual therapeutic strategy against Alzheimer disease 
were envisaged. 
 Activation of p53 tumor suppressor by antagonizing its negative 
regulators MDM2/X has been considered an attractive strategy for cancer 
therapy. Great effort has been given in the development of drugs able to 
dissociate the p53·MDM2/X complex. Under this regard, a simple and 
rapid technique to study the p53–MDM2/X interaction has been 
developed. This method is based on the different mobility between the 
interacting domains of the oncosuppressor p53 and its protein ligands 
MDM2/X on polyacrylamide gels under native conditions. While the two 
proteins MDM2/X alone were able to enter the gel, the formation of a 
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binary complex between p53 and MDM2/X prevented the gel entry. The 
novel technique is reliable for determining the different affinity elicited 
by MDM2 or MDMX toward p53, and for analyzing the dissociation 
power exerted by small molecules on the complex taking advantage of the 
appearance of migrating MDM2 or MDMX, when inhibitors are added to 
the complex mixture. Despite the fact that some other different methods 
have been employed to study this kind of interaction, including NMR 
technology, surface plasmon resonance or fluorescence polarization, the 
relevance of the method here described resides in the fact that it is much 
more simple and it does not require any tagging/derivatization procedure 
of the protein fragments employed. This simple and rapid technique can 
be useful to easily discriminate, among a library of compounds endowed 
with a potential pharmacological activity against cancer development, the 
molecules with the highest dissociative potency, preventing the use of 
expensive and more sophisticated technologies.  
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General introduction 
 Proteins play pivotal and essential roles in cellular activity. For 
this reason, protein–ligand interactions are fundamental for almost all 
processes occurring in living organisms. Ligand-mediated signal 
transmission through molecular complementary is essential to all life 
processes; these chemical interactions comprises biological recognition at 
molecular level. The evolution of the protein function is dependent in part 
on the development of highly specific sites designed to bind ligand 
molecules with affinities tuned to the needs of the cell. Ligand binding 
capacity is important for the regulation of biological functions. 
Regulation of cellular processes via cooperative protein–ligand 
interactions occurs through molecular mechanisms involving protein 
conformational transition among low– and high–affinity states. Ligand 
binding interactions changes the protein state and protein function. 
 Because protein-ligand interactions play a key role in cellular 
metabolism, detailed knowledge of such interactions, either at a 
microscopic and macroscopic level, is also required.  Important 
systems, which are now being studied at a molecular level, include ligand 
binding to structural proteins, protein-DNA binding, protein-saccharide, 
protein-protein, and protein-peptide interactions. 
 The term “ligand” in biological systems can have many different 
meanings. In its broadest sense, it is usually used to intend any molecule 
which interacts with a given molecule (in this case a protein). The term 
“ligand” thus includes other macromolecules (peptides/proteins/nucleic 
acids/lipids/carbohydrates or mixed molecular species thereof) as well as 
“small” molecular mass molecules (arbitrarily < 1-2 kDa). Ligands 
therefore comprise a very large and structurally diverse group of 
General Introduction 
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molecules which, unsurprisingly also display a wide variety of physic-
chemical characteristics. This makes it difficult to understand, delineate, 
and draw generalized conclusions concerning their biophysical properties. 
 When possible, the knowledge of the structure/conformation at the 
atomic level of the protein and the ligand in the unbound form represents 
a prerequisite for protein-ligand interaction studies. 
 For example, the structures of protein–ligand complexes at atomic 
resolution make possible the design of small!molecule drugs for the 
treatment of diseases. 
 The study of interactions between proteins and cellular molecules 
is fundamental to the understanding of biological systems. Drastically 
increased interest in this problem among investigators working in 
different fields of biological science needs to be supported by knowledge 
of biophysical tools and approaches dealing with protein interactions.  
 Protein-ligand interaction can be studied with a large variety of 
biophysical techniques such as the surface plasmon resonance (SPR), the 
isothermal titration calorimetry (ITC), the mass spectrometry (MS), the 
microscale thermophoresis (MST), the nuclear magnetic resonance 
(NMR), and so on. 
 Under this regard, the research work dealing with this PhD thesis is 
focused on the adaptation of common and simple biochemical techniques to 
the study the protein-ligand interactions involved in some frequent 
incidence diseases, such as Alzheimer’s disease and cancer. For both topics, 
the research approach was multidisciplinary, considering the partnership 
with other groups experienced in pharmacology, bio-informatics, organic 
chemistry, molecular biology, and of course, in biochemistry. 
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I.1 State of art on the Alzheimer’s disease 
 
 Alzheimer’s disease (AD), named after the doctor who first 
described it in 1907 (Alois Alzheimer), is a neurodegenerative disorder of 
the Central Nervous System (CNS). It is characterised by progressive 
deterioration of memory and higher cortical functions that ultimately 
result in total degradation of intellectual and mental activities. 
AD is the most common form of dementia. It is one of the major 
health problems in the economically developed countries along with 
cardiovascular disorders and cancer. In fact, it is estimated that currently 
about 36 million people in the world suffering from AD and it is expected 
that they will be 66 million in 2030 [Wold Alzheimer Report, 2011]. Its 
prevalence increases with age, from 10% at 65 years to nearly 50% at 85 
years [Bachurin, 2003; Colombres et al., 2004]. 
At the macroscopic level, in Alzheimer’s disease a variable degree 
of cortical atrophy, characterized by enlargement of the parietal grooves, 
more pronounced in the frontal lobes, temporal and parietal, can be 
observed. This atrophy is compensated by an enlargement of the 
ventricular cavities, secondary event to the loss of parenchyma. In 
particular, in the advanced stages of the disease, the structures of the 
medial temporal lobe, including the hippocampus, entorhinal cortex and 
amygdala, result severely atrophied, given their involvement starting from 
the earliest stages of the disease. 
Alzheimer’s disease also presents even microscopic changes, 
known as extracellular senile plaques and intracellular neurofibrillary 
tangles, which form the basis of histological diagnosis. When the 
progression of the disease occurs, a severe neuronal loss is accompanied 
by gliosis. 
Chapter I 
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The neuropathological characteristics keys of AD are senile 
plaques (SP), which are associated with beta-amyloid peptide, 
neurofibrillary tangles (NFT), and the loss of neurons in the hippocampus 
and nucleus basalis of Meynart [Selkoe, 1991; Goedert et al., 1996; 
Morrison et al., 1998]. Neurotransmitter specificity of AD is characterised 
by a pronounced degradation of cholinergic system and by disturbances 
of functions in other neurotransmitter systems, such as glutamatergic and 
serotoninergic systems [Dringenberg, 2000; Buccafusco & Terry, 2000]. 
According to the ‘‘cholinergic hypothesis’’, impairment in the 
cholinergic function is of critical importance in AD especially for the 
brain areas dealing with learning, memory, behaviour and emotional 
responses that include the neocortex and the hippocampus. Brain atrophy 
is the most obvious clinical finding in AD in which the levels of 
acetylcholine (ACh), a neurotransmitter responsible for the conduction of 
electrical impulses from one nerve cell to another nerve cell, are 
decreased due to its rapid hydrolysis by acetylcholinesterase (AChE) 
enzyme [Ladner & Lee, 1998].  
According to ‘‘amyloid hypothesis’’, AChE produces secondary 
non-cholinergic functions that include promotion beta-amyloid peptide 
(Ab) deposition in the senile plaques/neurofibrillary tangles in the brain 
of afflicted individuals [Castro & Martinez, 2001; Selkoe, 2002; Bartolini 
et al., 2003; Rees et al., 2003]. The deposition of Ab has been considered 
to play an important role in the initiation, as well as in the progression, of 
AD [Rees et al., 2003]. In addition, in the amyloid hypothesis the 
formation and the aggregation of the β-amyloid peptide (Aβ) 
[Eikelenboom et al., 2006] has been associated to the hydrolysis of the 
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Amyloid Precursor Protein (APP) by β-secretase 1 (BACE-1) [Vassar et 
al., 2004]. 
Butirrylcholinesterase (BuChE) is an enzyme closely related to 
AChE, working as a co-regulator of cholinergic neurotransmission by 
hydrolysing ACh [Mesulam et al., 2002]. The studies have shown an 
increased BuChE activity (40–90%) in the most affected areas of the 
brain, such as the temporal cortex and the hippocampus, during the 
development of AD. An increased BuChE activity plays also an important 
role in Ab-aggregation during the early stages of senile plaque formation 
[Geula & Darvesh, 2004]. Thus, AChE and BuChE inhibition have been 
documented as critical targets for the effective management of AD by an 
increase in the availability of ACh in the brain regions and decrease in the 
Ab deposition [De Ferrari et al., 2001]. However, BuChE is mainly 
localized in the peripheral tissues, including plasma, but accounting for a 
very small amount in the brain region. Therefore, the potential advantage 
of selective inhibition of AChE over BChE may include lower degree of 
associated side effects due to peripheral inhibition of cholinesterase 
enzyme [Anand & Singh, 2012b]. 
Nowadays, no cure for Alzheimer’s is so far available. 
Researchers are still trying to fully understand how the disease leads to 
memory loss and problems regarding thinking and behaviour, hoping to 
prevent or stop the disease. 
Some therapies ease the symptoms and help people to feel better 
for longer. Because the disease’s effects change over time, people often 
need personalised treatments which changes during time, when different 
related to AD problems emerge. 
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The current therapies for AD, still symptomatic and palliative, 
works, from one side, for the inhibition of AChE to restore the natural 
level of ACh [Bolognesi et al., 2002; Zhang & casida, 2005], and, from 
the other side, on the inhibition of Aβ aggregation [Eikelenboom et al., 
2006; Mancini et al., 2007]. Under this regard, efforts have been recently 
devoted to the development of dual inhibitors of AChE and BACE-1 [Zhu 
et al., 2009; Viayna et al., 2013; Ortega et al., 2011; Rampa et al., 2015; 
Nguyen et al., 2015]. 
The approved drugs against AD causes or effects can be divided in 
two classes: 
• drugs for Alzheimer’s disease; 
• drugs for other induced disorders. 
Acetylcholinesterase inhibitors are commonly used to treat mild to 
moderate stage of Alzheimer’s disease. These drugs increase the 
cholinergic transmission, delaying the degradation of acetylcholine. They 
maintain the availability of acetylcholine in the brain and can make up, 
but not stop, the cell destruction caused by the disease. 
The AChE drugs approved by the U.S. Food and Drug 
Administration (FDA) are: 
• Tacrine (in Italy is not available) 
• Rivastigmine 
• Galantamine 
• Donepezil 
Tacrine was the first centrally acting cholinesterase inhibitor 
approved for the treatment of Alzheimer’s disease in 1993 by the U.S. 
FDA, and was marketed under the trade name Cognex®. 
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Figure I.1. The structure of Tacrine 
 
Despite this drug is able to lead an improvement of cognitive 
functions, its side effects, particularly on the liver, doesn’t make it a first 
choice remedy. 
The rivastigmine, better known as Exelon®, is also used for 
Alzheimer’s disease, and it was observed that acts mostly on the brain 
areas such as hippocampus and cortex. 
 
 
Figure I.2. The structure of Rivastigmine  
One of the newer cholinesterase inhibitors is galantamine, 
approved by the FDA in 2001. This molecule is known by the trade name 
Reminyl
®, and it is a natural alkaloid found in Galanthus nivalis, a plant 
belonging to the family Amaryllidacea. Since its discovery, galantamine 
has been used for the treatment of myasthenia gravis (muscle weakness) 
and other neuromuscular diseases. For its ability to cross the blood-brain 
barrier (at the level of the central nervous system) and to selectively 
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inhibit AChE, its use in the treatment of Alzheimer’s disease has been 
suggested. It is a long lasting drug with activity on the central nervous 
system, devoid of toxicity at the hepatic level and with moderate side 
effects, similar to those of the other cholinesterase inhibitors. The 
administration of galantamine has prompted an increase of memory 
performance in treated subjects, leading to a reduction of the cognitive 
damage. 
 
 
Figure I.3. The structure of Galantamine 
 
Among the several drugs approved by the FDA-USA for the 
treatment of AD, the most recently one is donepezil, better known by the 
trade name Aricept®. Donepezil has a half-life of about 70 hours, that 
makes possible a only one daily administration. It acts in the early stage 
of disease, when it is still considered mild or moderate. At this stage the 
cognitive symptoms are still mild and the everyday life of the patient is 
not compromised. Furthermore, Donepezil has shown an excellent 
tolerability without hepatotoxicity and is considered the most effective 
inhibitor of the AChE currently available on the market [Sugimoto et al., 
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2000; Van der Zee et al., 2001]. Very recently donepezil has been 
proposed as soft inhibitor of β-secretase 1. 
 
 
Figure I.4. The structure of Donepezil 
 
The profile of the adverse effects of various acetylcholinesterase 
inhibitors is similar, and include gastrointestinal effects such as nausea, 
vomiting, weight loss and neurological effects including insomnia, 
headaches, dizziness, sweating. The choice of one or the other drug 
depends on the doctor and varies from individual to individual. The 
disadvantage of using these drugs is that their efficacy is related to the 
integrity of the nervous structures, which in the Alzheimer’s patient 
continue to degenerate, reducing the acetylcholinesterase inhibitors effect. 
Furthermore, another disadvantage is the lack of selectivity towards 
specific receptors. In particular, numerous scientific studies have shown 
that stimulation of muscarinic receptors of type M1, but not M2, is able to 
lead to a reduction in the levels of β–amyloid.  
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I.2 The aim 
The aim of the present work is to design, on the basis of molecular 
docking strategy, and to synthesize, through eco-friendly synthetic 
procedures, donepezil-like compounds as potential AChE and BACE-1 
inhibitors, in order to identify novel effective drugs for the treatment of 
AD. 
For all these compounds the evaluation of their inhibitory effect 
on the catalytic activity of cholinesterases was followed by 
spectrophotometric method, whereas that on β-secretase activity was 
monitored by spectrofluorimetric method. In addition, the effect on cell 
viability and the possible cytotoxicity on neurons cell line, has also been 
investigated. 
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I.3 Experimental 
 
I.3.a Materials  
All donepezil-like compounds have been synthesized and given by 
the research group of Professor Antonio Procopio of Department of 
Health Sciences, University of the Studies of Magna Graecia. All the 
compounds were identified by HR-MS and characterized by 1H-NMR and 
13C-NMR. 
AChE from Electrophorus electricus (eeAChE), and from human 
erythrocytes (hAChE), BuChE from horse serum, acetylthiocholine, 
butyrylthiocholine, 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB), 
Donepezil, the fluorescent peptide substrate containing the Lys-Met/Asn-
Leu mutations cleavage site of the amyloid precursor protein (APP) β-
secretase, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) and the Trypan blue dye (2,7-Naphthalenedisulfonic acid, 3,3'-
((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(5-amino-4-hydroxy-), 
tetrasodium salt) were purchased from Sigma-Aldrich. 
Mouse BACE-1 (recombinant) and BACE-1 Inhibitor I were from 
Life Technology, and BACE-1 inhibitor IV solution (10 mM in DMSO) 
was from Calbiochem.  
Stock solutions of the synthesized compounds were prepared in 
DMSO at 100 mM final concentration. 
 
I.3.b Enzymatic assays 
Cholinesterase activity was assayed by the Elmann method 
[Ellman et al., 1961] using acetylthiocholine or butyrylthiocoline as 
substrate for AChE or BuChE, respectively. The reduction of 
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dithiobisnitrobenzoate by the thiocholine, produced by the enzymatic 
hydrolysis of thiolated substrates, was followed colorimetrically (412 nm) 
at room temperature (22-27°C). The reaction mixture (500 µL) contained 
330 µM DTNB and the appropriate amount of substrate, in 0.1 M sodium 
phosphate buffer, pH 7.1. The reaction was started by the addition of 100 
mU/mL or 200 mU/mL of AChE or BuChE, respectively, and the initial 
rate of the reaction was derived from the linear portion of the kinetics. 
The reversibility of the inhibitory activity exerted by all 
synthesised compounds was assessed using a dilution method described 
previously [Sohn et al., 2003; Lavecchia et al., 2012]. Briefly, the enzyme 
was pre-incubated for 20 min with the inhibitors or with DMSO, as a 
vehicle control; after a 100-fold dilution of the reaction mixture, the 
residual enzyme activity was measured as reported above. 
The concentration of inhibitor required to reduce the enzymatic 
activity to 50% (IC50) was derived from semi-logarithmic plots in which 
the residual cholinesterase activity was determined at different 
concentration of inhibitor, using a thiolated substrate concentration of 500 
µM. Linear curve fits were obtained with the least-squares method, and 
the significance of the correlation was estimated from the squared 
correlation coefficient r2, which was always higher than 0.95.  
The kinetic parameters of the enzymatic reaction, Km and Vmax, 
were derived from the determination of the enzyme activity at 6 different 
acetylthiocholine or butyrylthiocholine concentration (80–500 µM), 
chosen in order to give the similar weight in the regression. The data were 
either interpolated in the Michaelis-Menten equation or treated with the 
Lineweaver-Burk equation giving similar results. 
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The inhibition constant Ki was derived by measuring the kinetic 
parameters in the presence of different inhibitor concentration, 0.2 – 30 
µM for AChE or 3 – 100 µM for BuChE. The values of Ki were derived 
from the equation Km' = Km (1 + [I]/Ki), in case of competitive inhibition 
or Vmax' = Vmax / (1 + [I]/Ki), in case of non-competitive inhibition, or with 
both in the case of mixed inhibition. In these equations Km' and Vmax' 
represent the values of Km and Vmax measured at the [I] concentration of 
inhibitor. Values of IC50 and Ki reported were the mean of at least 4 
different determinations. 
BACE-1 activity was assayed by a fluorimetric method [Mancini 
et al., 2007] using the Enspire™ Multimode Plate Reader (Perkin-Elmer) 
in the kinetic Fluorescence method. The assay was performed in black 
polystyrene 96-well microtiter plates. The reaction mixtures contained 2.1 
ng/µL mouse BACE-1 in 50 mM ammonium acetate buffer, pH 4.5, 
supplemented with 1 mM triton X-100, and the appropriate amount of the 
inhibitor. The mixture was incubated for 10 min at room temperature (22-
25°C), the reaction started by adding 100 nM final concentration of the 
fluorescent peptide substrate, and the increase in fluorescence was 
followed kinetically. The enzymatic cleavage of the peptide led to the 
appearance of a fluorescence signal using excitation and emission 
wavelength of 320 and 420 nm, respectively. The rate was derived from 
the linear portion of the kinetics, usually in the first 30 min of the 
reaction. The known Inhibitors I (IC50, 240 nM) [Lavecchia et al., 2012], 
and IV (IC50, 15 nM) [Stachel et al., 2004], were used as positive 
controls. 
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I.3.c Proliferation and viability assays 
The effect of the synthesized compounds on proliferation and 
viability was assessed in SH-SY5Y neuroblastoma cells. Cells were 
grown in Roswell Park Memorial Institute medium (RPMI) supplemented 
with 2 mM L-glutamine, 100 UI/mL penicillin, 100 µg/mL streptomycin 
and 10% (v/v) fetal bovine serum. Cells were maintained in culture dishes 
Petri 100 mm, at 37 °C in a saturated humidity atmosphere containing 
95% air and 5% CO2. Cells were seeded at an initial density of 10
4 
cells/cm2 in culture dishes. At a confluence of 80%, cells were detached 
by trypsin treatment, suspended in fresh medium without FBS and 
transferred to multiwell (6, 12 or 96 wells) according to the experimental 
requirements. After 24h from seeding, cells were incubeted with different 
synthesized compounds for 24-48 hours using 0.1% (v/v) DMSO as 
vehicle. 
The effect of synthesized compounds on cell proliferation was 
evaluated as mitochondrial activity using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay [Mossman, 
1983]. Briefly, after the treatment, the medium was removed and cells 
were incubated with 100 µL MTT solution (0.5 mg/mL) for 1 h. After 
that, the solution was removed, the formed formazan was solubilized in 
100 µL of 0.1 N HCl in 90 % (v/v) 2-propanol and the absorbance 
measured at 570 nm using a microplate reader (BioRad). 
Vice versa, cell viability was evaluated using Trypan blue 
exclusion method [Strober, 2001] based on the principle that living cells 
possess intact cell membranes avoid the entrance of the dye, whereas 
dead cells does, rendering blue their cytosol. After the incubation with the 
compounds, the medium was removed to eliminate cells in suspension, 
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and the adherent cells were detached through trypsin treatment. The cell 
suspension was then centrifuged at 1200 rpm for 5 minutes and the cell 
pellet was resuspended with 0.4% (p/v) of Trypan blue. 
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I.4  Results and Discussion 
 
I.4.a Synthesis of Donepezil analogues 
In the last decade, it has spent a lot of effort in the synthesis of 
pharmacologically active molecules through eco-friendly synthetic 
procedures in agreement with the known principles of green chemistry 
[Procopio et al., 2014; Nardi et al., 2011; Cravotto et al., 2011; Oliviero et 
al., 2014]. Thus, inspired by this philosophy, it was designed the general 
synthetic pathway for the novel donepezil derivatives depicted in Fig. I.5. 
The X-ray crystallographic studies for a large number of AChE–
ligand complexes show as two main binding sites the catalytic binding 
site (CAS), comprising the Ser-His-Glu catalytic triad, and the 
secondary/peripheral anionic binding site (PAS), connected by a deep, 
hydrophobic gorge [http://www.rcsb.org/pdb/home/home.do]. Donepezil, 
(RS)-2-[(1-benzyl-4-piperidyl) methyl]-5,6-dimethoxy-2,3-dihydroinden-
1-one, known also as E2020, can interact with both the sites: the N-benzyl 
piperidine residue binds to the CAS of AChE, whereas the hydrophobic 
aromatic part (5,6-dimethoxyindan-1-one) binds to the PAS [Koellner et 
al., 2000, Saxena et al., 2003]. 
Based on these observations, a series of indanone and piperidine 
derivatives bearing electron-donating groups on the different positions of 
the respective aromatic rings, which would lead to the synthesis of 
various derivatives of donepezil by aldol condensation, were designed 
(Fig. I.6).  
The general structure of the designed compounds (Fig. I.6) 
maintains the N-benzyl piperidine and indanone moieties of the donepezil 
structure identified as important interactions binding sites with AChE but 
the stereocenter between them was eliminated, because there are no 
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evidences about its role in donepezil binding action. In all the synthesized 
compounds an unsaturation was located between the indanone and 
benzilpiperideine moieties, leading to a more rigid structure. It has been 
recently proposed that donepezil analogues with a double bond on the 
indanone moiety can act as BACE-1 inhibitors due to their structural 
rigidity. Two series of Donepezil like compounds were devoleped and 
synthesized: a methoxyl 10-components series, characterized by the 
presence of methoxyl groups in different structural positions (GP9, GP10, 
GP11, GP12, GP13, GP15, GP16, GP17, GP18, GP19). 
On the basis of molecular docking analysis these modifications 
should ensure a better interaction with the cholinesterase and BACE-1 
catalytic sites.  
Finally, with the aim at improving compound solubilisation, a 
different phenolic 4-components series was synthesized (DEMG3, 
DEMG5, DEMG6, DEMG7), in order to study if a stronger H-donor 
group can influence the binding on the CAS. According to the docking 
studies performed on these molecules, the amino substituent reached the 
enzyme active site, while the indanone substituents were exposed to the 
solvent [Rampa et al., 2015]. For this reason it was decided to test the 
new donepezil analogues also against BACE-1 activity. 
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Figure I.5. Synthetic pathway for the total synthesis of Donepezil 
analogues 
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Figure I.6. Chemical structure of designed Donepezil analogues 
 
I.4.b Effect of the synthesized compounds on the kinetic parameters of 
cholinesterases 
To test the inhibition power of synthesized compounds, the 
Electrophorus electricus and human acetylcholinesterase (eeAChE, 
hAChE respectively) activity was measured in the absence or in the 
presence of 1 µM of each compound; when butyrylcholinesterase for 
horse serum (BuChE) activity was tested, the 2 µM concentration of each 
compound was used. 
The effect of the inhibitors on cholinesterases activity was 
compared to that exhibited by Donepezil (Fig. I.7). Among the tested 
compounds, GP10, GP9, GP11, and DEMG6 (see Fig. I.5 for their 
molecular structures) exhibited the highest inhibition on hAChE activity, 
with an estimated IC50 below 1 µM, therefore approaching that of 
Donepezil (Panel A, Fig. I.7). 
In the case of eeAChE, in addition to the above mentioned 
compounds, also GP12 exhibited one of the greatest inhibitory activity 
(Panel B, Fig. I.7); although the inhibitory effect was lower than that 
exhibited by donepezil, their IC50 still remain below 1 µM.  
Chapter I 
 23 
Concerning BuChE activity, the inhibition power of all the 
synthesized compounds was always lower (Panel C, Fig. I.7), being the 
IC50 values higher than 2 µM. 
As demonstrated by the dilution method (see section 3.I.2), the 
inhibitory effect observed was reversible for all cholinesterases tested 
because the activity was recovered after a 100-fold dilution of every 
added compound; the only exception was observed for Donepezil effect 
on both eeAChE and hAChE, since 10 nM final concentration still 
inhibiting this enzymatic activity (not shown). 
Therefore, in order to determine the IC50 of the synthesized 
compounds on cholinesterases, the residual enzymatic activity was 
assessed following the addition of different amounts of the inhibitors to 
the reaction mixture. In Panels A (methoxylic derivatives) and B 
(hydroxylic derivatives) of Fig. I.8 the effect on eeAChE activity was 
shown; the data were then treated in a semilogarithmic plot (Panel C and 
D, Fig. I.8), in order to extrapolate the values of the IC50. 
The results obtained from the experiments on eeAChE were 
reported in Table I.1. Those obtained from the similar experiments carried 
out on hAChE and BuChE (not shown), were instead reported in Table 
I.2. 
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Figure I.7. Inhibition of the cholinesterase activity exerted by 
synthesized compounds.  
The cholinesterase activity was determined in the absence or in the 
presence of the indicated compounds. Panel A: effect on eeAChE activity 
due by compounds added to 1 µM final concentration; panel B: effect on 
hAChE activity due by compounds added to 1 µM final concentration; 
panel C: effect on BuChE activity due by compounds added to 2 µM final 
concentration. The data represent the average of at least three different 
determinations. Further experimental details are given in section I.3.b. 
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Figure I.8. Determination of the IC50 of the synthesized compounds. 
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Table I.1. Inhibition parameters of synthesized compounds on the activity 
of eeAChE 
 
 
 
Table I.2 Inhibition parameters and selectivity of synthesized compounds on the 
activity of hAChE and BuChE. 
 
  
 eeAChE 
Inhibitor Ki (µM) IC50 (µM) 
Donepezil 0.031 ± 0.022 0.029 ± 0.005 
DEMG3 4.400 ± 1.350 2.825 ± 0.625 
DEMG5 1.537 ± 0.248 1.249 ± 0.031 
DEMG6 0.327 ± 0.010 0.327 ± 0.018 
DEMG7 1.417 ± 0.161 1.977 ± 0.173 
GP9 0.212 ± 0.078 0.163 ± 0.058 
GP10 0.289 ± 0.035 0.331 ± 0.121 
GP11 0.426 ± 0.149 0.420 ± 0.294 
GP12 3.680 ± 2.350 0.992 ± 0.131 
GP13 1.100 ± 0.360 1.430 ± 0.350 
GP15 4.125 ± 3.278 6.610 ± 0.099 
GP16 1.912 ± 1.128 3.520 ± 0.022 
GP17 1.023 ± 0.386 1.748 ± 1.174 
GP18 37.453 ± 21.43 40.353 ± 33.63 
GP19 20.12 ± 9.43 11.083 ± 1.595 
 
 
 hAChE Bu ChE Selectivity* 
Inhibitor 
 
Ki 
(µM) 
IC50 
(µM) 
Ki 
(µM) 
IC50 
(µM) 
From 
Ki 
From 
IC50 
Donepezil 0.010 ± 0.006! 0.011 ± 0.008 2.140 ± 1.380 1.270 ± 0.410 214 120 
DEMG3 2.822 ± 0.022 1.540 ± 0.090 10.611 ± 4.205 7.350 ± 0.130 4 5 
DEMG5 4.224 ± 1.920 1.500 ± 0.23 5.613 ± 1.294 5.800 ± 0.050 1 4 
DEMG6 0.355 ± 0.035 0.636 ± 0.209 6.480 ± 2.420 4.760 ± 0.041 18 7 
DEMG7 1.980 ± 0.180 2.160 ± 0.760 8.460 ± 3.930 7.590 ± 0.03 4 4 
GP9 0.035 ± 0.008 0.058 ± 0.033 2.440 ± 1.290 4.740 ± 0.750 71 81 
GP11 0.260 ± 0.036 0.342 ± 0.029 1.140 ± 0.052 2.650 ± 0.617 4 8 
GP12 1.835 ± 0.597 1.509 ± 0.510 3.099 ± 2.610 1.140 ± 0.090 2 1 
GP10 0.029 ± 0.007 0.043 ± 0.007 3.140 ± 1.800 5.734 ± 0.130 110 132 
GP17 0.980 ± 0.220 0.755 ± 0.025 7.254 ± 4.572 15.130 ± 0.025 7 20 
GP13 0.554 ± 0.052 0.853 ± 0.052 3.490 ± 2.240 2.170 ± 1.330 6 3 
GP15 119.490 ± 61.030 34.500 ± 18.470 3.888 ± 3.110 1.620 ± 0.004 <1 <1 
GP16 17.230 ± 6.420 12.155 ± 0.225 2.378 ± 1.730 5.410 ± 0.120 <1 <1 
GP19 39.670 ± 12.040 25.195 ± 21.720 4.328 ± 2.969 9.820 ± 0.200 <1 <1 
GP18 18.200 ± 7.640 11.135 ± 0.054 6.437 ± 2.633 4.820 ± 0.002 <1 <1 
*The selectivity was derived from the ratio KiBuChE/KiAChE. 
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The data on selectivity reported in the Table I.2 indicated that, 
among the Donepezil analogues synthesized, GP9 and GP10 resulted 
about two orders of magnitude more selective for AChE than BuChE, 
therefore approaching the selectiveness displayed by Donepezil. 
In order to assess the mode of inhibition, the effect of different 
concentration of the compounds was tested at various thiolated substrate 
concentrations, allowing the determination of the Ki. Concerning the 
effect of Donepezil on cholinesterase activity a representative plot of the 
above mentioned experiments is reported in Figure I.9. The data were 
either interpolated in the Michaelis-Menten equation or treated with the 
Lineweaver-Burk equation giving similar results. 
The data indicated that among the inhibitors, GP17, GP18, and 
GP19 acted as mixed inhibitors of hAChE, as Donepezil did; vice versa, 
the other synthesized compounds showed a non-competitive behaviour of 
the inhibition (not shown). 
Concerning the effect on BuChE, DEMG6, DEMG7, GP9, 
GP11, and GP12 exhibited a mixed inhibition mechanism, as Donepezil 
did. The remaining compounds acted as no competitive inhibitors except 
for GP16, which showed a competitive inhibition mechanism on BuChE. 
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Figure I.9. Determination of the kinetic parameters. The kinetic 
parameters were determined as reported in the Experimental section I.3.b. 
Representation of the data with Michaelis-Menten equation (left panels) 
and Lineweaver-Burk equation (right panels) of Donepezil on eeAChE, 
hAChE, and BuChE activity (Panel A, B and C, respectively). 
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I.4.c Effect of the synthesized compounds on BACE-1 activity 
Using a different experimental approach, the effect of the 
inhibitors on BACE-1 activity was checked and compared to that 
exhibited by Donepezil (Fig. I.10). Among the tested compounds 
DEMG6, DEMG 7, GP9, GP10, GP12 and GP17, exhibited the highest 
inhibition activity, with an estimated IC50 below 1 µM, therefore 
approaching to that shown by Donepezil [Mancini et al., 2007]. 
Moreover, compared to those reported in the literature for structurally 
similar molecules, compounds GP9 and GP10 displayed a better dual 
activity and lower IC50 values against both AChE and BACE-1 enzymes 
[Rampa et al., 2015]. 
 
Figure I.10. Effect of synthesized compounds on BACE-1 activity. 
The BACE-1 activity was determined as reported in the Experimental 
section I.3.b in the absence or in the presence of 1 µM synthesized 
compounds. The residual activity was compared to that exhibited by 
Donepezil (200 nM) or the known Inhibitor I (1 µM) and IV (100 nM) of 
BACE-1 activity as a positive control. The data represent the average of 
at least three determinations and the significance of the data was 
evaluated by p value (*, < 0.05; **, < 0.005; ***, < 0.0005). 
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I.4.d Effect of the synthesized compounds on proliferation and cell 
viability of SH-SY5Y neuroblastoma cells 
The effect of the synthesized compounds on proliferation and cell 
viability was evaluated in SH-SY5Y neuroblastoma cells. In preliminary 
experiments, the effect of some synthesised compounds (GP9, GP10, 
GP11, GP12, GP13) was tested adding these molecules at a final 
concentration ranging from ½– to ten–times their IC50 values exhibited 
towards AChE activity (see Table I.1). 
The data showed that none of the inhibitors tested significantly 
interferes with the proliferation of SH-SY5Y cells up to 48h (Fig. I.11). 
Finally, the effect of synthesized compounds on SH-SY5Y cell 
viability was evaluated using Trypan blue exclusion test. Preliminary 
results, although not indicating any effect of on cell viability, show that 
these molecules induce a change in cell morphology (Fig. I.12) passing 
form a round shaped form to an elongated one.  
 
Figure I.11. Effect of synthesized compounds on SH-SY5Y cell 
proliferation. 
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Figure I.12. Effect of synthesized compounds on SH-SY5Y 
cell viability.  
Panel A: control cells; panel B: cells treated with the compound GP10. 
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Native PAGE to study the interaction between 
the oncosuppressor p53 and its protein ligands 
and the dissociation of the complexes by 
potentially anticancer compounds 
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II.1 State of art on the methods useful to study the association/ 
dissociation of p53 complexes  
Human p53 is a nuclear phosphoprotein of MW 53 kDa, it was 
first identified in 1979 by Arnold Levine, David Lane, and Lloyd Old [De 
Leo et al., 1979]. However its existence was hypothesized first as a target 
of the oncogenic virus SV40, a strain capable of inducing the 
development of tumors [Lane & Crawford, 1979; Linzer & Levine, 1979]. 
Wild-type p53 protein contains 393 amino acids, consisting of three 
functional domains: an N-terminal activation domain, DNA binding 
domain, and C-terminal tetramerization domain [Slee et al., 2004; Bode & 
Dong, 2004; Vousden & Lu, 2002]. The p53 tumor suppressor belongs to 
a small family of related proteins that includes two other members: p63 
and p73. Although structurally and functionally related, p63 and p73 have 
clear roles in normal development, whereas p53 seems to have evolved in 
higher organisms to prevent tumour development. In fact, p53 protein is 
involved in a number of physiological processes [Vousden & Lu, 2002; 
Vogelstein et al., 2000], and its inactivation/mutation represents one of 
the most common molecular switch leading to tumorigenesis [Bieging & 
Attardi, 2012]. As it is involved in roughly one-half of cancers, a great 
effort has been devoted to the development of strategies targeting the p53 
reactivation. 
As a tumor suppressor, p53 is essential for preventing 
inappropriate cell proliferation and maintaining genome integrity 
following genotoxic stress [Bai & Zhu, 2006]. p53 is activated in 
response to several malignancy-associated stress signals, resulting in the 
inhibition of tumour-cell growth. Several responses can be provoked by 
p53, including cell-cycle arrest, senescence, differentiation and apoptosis, 
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with the option chosen being dependent on many factors that are both 
intrinsic and extrinsic to the cell. Under some circumstances, p53 also 
contributes to the repair of genotoxic damage, potentially allowing for the 
release of the rehabilitated cell back into the proliferating pool. In most 
cases, however, induction of p53 leads to an irreversible inhibition of cell 
growth, most decisively by activating apoptosis [Vousden & Lu, 2002]. 
Under normal physiological conditions, wild-type p53 protein 
levels must be kept low owing to its growth-inhibitory activities, and this 
control is mainly modulated via regulation of p53 protein stability. 
Although a number of different regulators have been reported to be 
involved in this protein regulation, MDM2 has been shown to be the 
principal player in control of p53 turnover [Levine & Oren, 2009]. 
In fact, probably the most important protein-protein interaction of 
p53 was discovered, when the MDM2 protein, previously described as a 
putative oncoprotein, was shown to bind tightly to p53 and inhibit its 
biochemical activity. MDM2 can inhibit p53 activity by a variety of 
means. First, by binding to the transactivation domain of p53, hence it 
sterically blocks the function of that domain. Moreover, by acting as a 
p53-specific E3 ubiquitin ligase, MDM2 promotes its ubiquitylation and 
subsequent proteasomal degradation. At the same time, p53 induces the 
expression of the Mdm2 gene, forming a negative feedback loop [Levine 
& Oren, 2009]. 
In 1996, MDM2 was joined by a new homologue, MDMX 
(MDM4 in the mouse). Like MDM2, MDMX too binds to the N terminal 
region of p53 and inhibits its activity. While MDMX does not possess 
measurable E3 activity, it does contribute to p53 degradation; apparently, 
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dimerization with MDMX augments the E3 ligase activity of MDM2 
[Levine & Oren, 2009]. 
Although a common mechanism involving the binding of the N-
terminal hydrophobic domains of MDM2 and/or MDMX to the p53 
transactivation domain can be found, several differences can be 
highlighted between these two inactivators. In addition, a cross-talk 
between MDM2 and MDMX in targeting p53 is an emerging important 
finding since it has been implicated in tumorigenesis, therefore, it 
represents an exciting opportunity in cancer therapy [Wang, 2011; Wang 
et al., 2012]. 
Since MDM2 and MDMX play a primary role in inhibition of the 
p53 tumor suppressor function, blockade of the MDM2/MDMX–p53 
protein-protein interaction would liberate p53 from its negative 
regulators, restoring the tumor suppression function. 
The interaction between MDM2/X and p53 has been mapped 
[Kussie et al., 1996], and on these bases several MDM2/X inhibitors have 
been designed [Wade et al., 2013], many of which have been submitted to 
human clinical trials. In fact, almost 10 years later, agents designed to 
block the MDM2–p53 interaction may have a therapeutic potential 
application in the discovery of substances with pharmacological activity 
against cancer development [Vassilev et al., 2004; Wade et al., 2013; 
Graves et al., 2013; Zhao et al., 2015]. 
Therefore, a number of techniques have been developed to study 
the formation and the dissociation of the complexes between these 
proteins. 
Nowadays, the association between the interacting domain of p53 
and its protein partners MDM2 and MDMX is studied by different 
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methods. The same several methodological approaches have been 
proposed, even to study the dissociation of the p53•MDM2/X complex 
exerted by molecules with potential pharmacological activity. In 
particular, nuclear magnetic resonance technology [Daniele et al., 2014], 
surface plasmon resonance [Vassilev et al., 2004], and fluorescence 
polarization [Reed et al., 2010] were used to this aim. 
Nuclear Magnetic Resonance spectroscopy, most commonly 
known as NMR spectroscopy is a powerful and theoretically complex 
analytical tool. This research technique exploits the magnetic properties 
of certain atomic nuclei. It determines the physical and chemical 
properties of atoms or the molecules in which they are contained. It relies 
on the phenomenon of nuclear magnetic resonance and can provide 
detailed information about the structure, dynamics, reaction state, and 
chemical environment of molecules. The intramolecular magnetic field 
around an atom in a molecule changes the resonance frequency, thus 
giving access to details of the electronic structure of a molecule. Most 
frequently, NMR spectroscopy is used by chemists and biochemists to 
investigate the properties of organic molecules, although it is applicable 
to any kind of sample that contains nuclei possessing spin. NMR spectra 
are unique, well-resolved, analytically tractable and often highly 
predictable for small molecules. Thus, in organic chemistry practice, 
NMR analysis is used to confirm the identity of a substance. A 
disadvantage is that a relatively large amount, 2–50 mg, of a purified 
substance is required, although it may be recovered. Preferably, the 
sample should be dissolved in a solvent, because NMR analysis of solids 
requires a dedicated MAS machine and may not give equally well-
resolved spectra. The timescale of NMR is relatively long, and thus it is 
Chapter II 
 37 
not suitable for observing fast phenomena, producing only an averaged 
spectrum. Although large amounts of impurities do show on an NMR 
spectrum, better methods exist for detecting impurities, as NMR is 
inherently not very sensitive. Finally, NMR spectrometers are expensive. 
The ability of the novel compounds to dissociate the MDM2/p53 
complex was investigated by NMR and ELISA-based in vitro assays on 
recombinant and native human MDM2/p53 complex, respectively 
[Daniele et al., 2014]. 
The inhibition of MDM2-p53 binding was analysed also with 
Biacore’s surface plasmon resonance technology in a solution 
competition format. 
Surface Plasmon Resonance (SPR) is a physical process that can 
occur when plane-polarized light hits a thin metal film under total internal 
reflection conditions. The most common use for SPR sensing is to 
evaluate protein-ligand [Jung et al., 2000], protein-protein [Karlsson & 
Falt, 1997], or nucleotide hybridization [Moon et al., 2010] events. Since 
it is typically not advantageous to directly deposit biological molecules 
onto surfaces, especially surfaces of inert metals such as silver or gold, 
surface functionalization can be used to create a more functionally active 
environment and reduce non-specific binding on the surface. 
Advancements in surface chemistry have allowed researchers to easily 
customize a sensing surface to their particular needs.  In recent 
years, the information obtained from SPR has also been used to 
complement the information obtained from mass spectrometry (MS), 
providing both quantitative and qualitative information. The combined 
use of SPR and MS can be used for functional proteomic screening, 
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identifying protein-protein interactions and further characterizing 
domains involved in the interactions. 
Historically, it has been difficult to develop small-molecule 
inhibitors of non-enzyme protein-protein interactions. However, the 
crystal structure of MDM2 bound to a peptide from the transactivation 
domain of p53 [Kussie et al., 1996] has revealed that MDM2 possesses a 
relatively deep hydrophobic pocket that is filled primarily by three side 
chains from the helical region of the peptide. 
Fluorescence polarization (FP) is a homogeneous method that 
allows rapid and quantitative analysis of diverse molecular interactions 
and enzyme activities. This technique has been widely utilized in clinical 
and biomedical settings, including the diagnosis of certain diseases and 
monitoring therapeutic drug levels in body fluids. Recent developments in 
the field has been symbolized by the facile adoption of FP in high-
throughput screening (HTS) and small molecule drug discovery of an 
increasing range of target classes. 
Using this approach, it was identified the first MDMX inhibitor, 
SJ-172550, and demonstrated that it can efficiently kill MDMX-amplified 
retinoblastoma cells. SJ-172550 functions in an additive manner with the 
MDM2 inhibitor nutlin-3a, thereby confirming the importance of 
targeting both of these negative regulators of p53 in cancer cells. This 
validated MDMX inhibitor provides a valuable lead compound and 
chemical scaffold for further chemical modification to develop a high 
affinity MDMX inhibitor with good bioavailability, pharmacokinetics, 
and pharmacodynamics [Reed et al., 2010]. 
Chapter II 
 39 
II.2 The aim 
The aim of the present work is to propose a new approach for 
studying the interaction between p53 and MDM2/X. The method is based 
on the different mobility between the interacting domains of the 
oncosuppressor p53 and its protein ligands MDM2/X on polyacrylamide 
gels under not denaturing conditions.  
The novel technique is reliable for determining the different 
affinity elicited by MDM2 or MDMX toward p53, and can be useful for 
analysing the dissociation power exerted by other molecules on the 
p53•MDM2/X complex. It was also investigated if this technique was 
reliable to determine the dissociative power exerted by small molecules 
on the complex, when inhibitors are added to the complex mixture. 
Therefore, it is proposed a new approach to easily screen library of 
compounds, with potential pharmacological anticancer activity.  
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II.3 Experimental 
 
II.3.a  Materials 
The protein fragments used in this work were heterologously 
expressed in Escherichia coli using derivatives of the pET-46Ek/LIC 
vector, in which the nucleotide sequence corresponding to the residues 1–
118 of MDM2 (Uniprot accession no. Q00987), 18–102 of MDMX 
(O15151), and 1–321 of p53 (P04637) was cloned. In the recombinant 
plasmids, the MAHHHHHHVDDDDK peptide was introduced at the N-
terminal of the amino acid sequence of each protein fragment, which 
allowed the fast purification of the expressed proteins by affinity 
chromatography. In the case of MDMX, the additional dipeptide IM was 
inserted at the beginning of the translated amino acid sequence. The 
plasmids were then used to transform the E. coli BL21 (DE3) RIL strain 
in which protein expression can be induced by IPTG. Antibodies anti-p53 
(A2413 from mouse, monoclonal antibody), anti-MDM2 (LS-C1722 from 
rabbit, polyclonal), and anti- MDMX (7632 from mouse, monoclonal) 
were used according to the following dilutions of 1:1000, 1:500,1:500, 
respectively, and were purchased from Abcam (Massachusetts,US). 
Nutlin-3a and Nutlin-3b were from Selleckchem, RO-5963 was 
from Calbiochem and all the other reagents of electrophoretic and/or 
molecular biology grade were from Sigma-Aldrich. Stock solutions of the 
inhibitors were prepared in DMSO at 100 mM final concentration. 
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II.3.b Heterologous expression and purification of p53, MDM2 and 
MDMX protein fragments 
Purified protein fragments were obtained using the procedure 
previously reported by Daniele et al. [Daniele et al., 2004] with some 
exceptions. Briefly, bacterial cells from two liters cultures were disrupted 
by French-Press (Aminco), and the inclusion bodies were prepared by 
centrifugation at 30 000 × g for 1.5 h. Each pellet was suspended with 5–
10 mL of a buffer containing 20 mM Tris–HCl, pH 7.2, 20 mM β-
mercaptoethanol, 1 mM PMSF, 1 mM EDTA, and 8 M urea, and 
centrifuged at 30 000 × g for 1.5 h. The supernatant was incubated with 1 
mL of Ni-NTA agarose (Qiagen) over night at 4°C. The slurry was 
poured into a column, and the packed resin was washed with the above 
buffer supplemented with 10 mM imidazole. Bound proteins were then 
eluted with the same buffer in which the concentration of imidazole was 
raised to 250 mM. Fractions (2 mL) were collected and analysed for 
purity on 12% w/v SDS-PAGE. The richest and purest fractions (usually 
the first two or three) were pooled together, diluted (1:5, v/v) with the 
elution buffer and dialyzed for 2 h at room temperature against the same 
buffer in which the urea concentration was lowered to 4 M to start 
renaturation. This was achieved by five dialysis steps at room temperature 
in which the urea concentration was progressively reduced to 0 M. In the 
final dialysis step (at 4°C), the buffer was added with 0.5 mM Tris (2-
carboxyethyl) phosphine as reducing agent in place of β-mercaptoethanol.  
The final protein solutions were concentrated by Centriprep® 10K 
(Amicon, Germany) up to 1 mg/mL for p53, and 0.5 mg/mL for both 
MDM2 and MDMX.  
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The concentrated samples were centrifuged to remove any un-
renatured material and stored at 4°C; they were used within 1 month of 
preparation, before onset of protein precipitation occurred.  
Protein concentration was calculated on the basis of the molar 
extinction coefficient (ε280nm) derived from the amino acid sequence of the 
three protein fragments using the ProtParam software available at 
www.swissprot.org. In particular, values of 28420, 10430, and 7450 L 
mol−1 cm−1 were calculated for p53, MDM2, and MDMX, respectively. 
 
II.3.c PAGE under native conditions and densitometric assay 
Electrophoresis was carried out on polyacrylamide gels casted 
without the stacking gel using the Mini PROTEAN® System of Bio-Rad 
Laboratories (USA). The separation gel (8 × 7 cm), which was prepared 
in 375 mM Tris–HCl buffer, pH 8.8, contained 12% w/v acrylamide, 
0.3% w/v bisacrylamide, and was polymerized by adding 0.05% v/v 
TEMED and 0.2% w/v ammonium persulfate. Prior the loading, each 
sample was incubated for 15 min at 37°C, and added of 8% v/v glycerol; 
0.05% w/v bromophenol blue was added to some samples as tracking dye. 
The electrophoresis run was carried out at 4°C at a constant voltage of 
150 V and was stopped after 30 min the tracking dye exited the gel. After 
the run, protein bands in the gel were fixed and stained with 0.5% w/v 
CBB-R in 50% v/v methanol and 10% v/v acetic acid and destained with 
30% v/v methanol and 7.5% v/v acetic acid.  
Gels were dried under vacuum and scanned at 720 dpi. Protein 
bands were quantified using the ImageJ software (1.43u version) freely 
available online (http://rsb.info.nih.gov/ij). 
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II.3.d Formation of the p53•MDM2/X complex and dissociation by 
potentially anticancer compounds 
Complex formation was attained by incubating protein fragments 
at appropriate molar ratios, for 30 min at 37°C.  
To check the effect of Nutlin-3a, Nutlin-3b, and RO-5963 as 
dissociation agents on the p53•MDM2/X complex, they were added to the 
reaction mixture at a concentration range in line with that used for the 
same inhibitors, whose effect has been evaluated by other techniques 
[Vassilev et al., 2004; Daniele et al., 2014]. In particular, in every gel, 11 
different concentration of Nutlin-3a (in 40–333 µM range), Nutlin-3b (in 
1.3–1667 µM range), or RO-5963 (in 0.104–3.3 µM range), respectively, 
was added to p53·MDM2 complex. Concerning p53•MDMX complex, 
the dissociation agents were added to the reaction mixture at different 
final concentrations; in particular, Nutlin-3b was added in a 133–1667 
µM range, Nutlin-3a in a 5–667 µM range, and RO-5963 in a 0.104– 3.3 
µM range, respectively, .  
The incubation was further prolonged for 15 min at 37°C. At all 
the concentration used, the effect of the DMSO carried over with the 
inhibitor concentration was assessed. The mixture of glycerol (8% v/v) 
and bromophenol blue (0.05% w/v) was added to some samples as 
tracking dye and then loaded on a 12% polyacrylamide gel (8 × 7 cm, 1-
mm thick). 
The electrophoresis run and the densitometric quantification of 
protein bands, was carried out as reported above (Experimental section 
II.3.c). 
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II.4 Result and Discussion 
 
II.4.a Characterization of purified p53, MDM2, and MDMX protein-
fragments  
The p53, MDM2, and MDMX protein fragments used in this 
thesis, corresponded to those involved in the protein-protein interaction. 
In particular, through molecular biology techniques, a stop codon was 
inserted after residue 118, 111, and 321 in the nucleotide sequence of the 
genes encoding MDM2 (Fig. II.1, panel A), MDMX (Fig. II.1, panel B), 
and p53 (Fig. II.1, panel C). In addition, a peptide spanning 14-15 
residues containing six histidine, was inserted at the N-terminus of the 
fragment, to allow protein purification through affinity chromatography 
(see Experimental section II.3.b for other details). 
The purified protein fragments appeared homogeneous on SDS-
PAGE (Fig. II.2), and the calculated molecular mass are in good 
agreement with those derived from the amino acid sequence. 
The identification of purified p53, MDM2, and MDMX protein 
fragments was obtained by both dot-blotting analysis and MALDI-TOF. 
In particular, using p53, MDM2, and MDMX antibodies, each purified 
protein immuno-reacted with its specific antibody, although a slight 
cross-reaction was found between the p53 antibody and MDM2 protein 
fragment (Fig. II.3). In addition, MALDI-TOF experiments gave 
molecular masses and fragmentation patterns expected for all protein 
fragments (Fig. II.4). 
In Table II.1 is reported a comparison between the determined 
molecular masses of the protein fragments with different methods and 
those derived from the amino acid sequence. From the analysis of the data 
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it emerged a discrepancy between the values derived from SDS-PAGE 
and the other methods for p53 and MDM2. These findings could be 
related to the fact that these proteins underwent different hydrodynamic 
behaviour during electrophoresis migration. However, it cannot be 
excluded that the formation of stable aggregates of p53 or MDM2 
impaired SDS denaturation prior the migration. 
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Figure II.1. Mapping of the MDM2 (Panel A), MDMX (Panel B) and 
p53 (Panel C) amino acids regions. Black shadowed residues have been 
inserted in the expressing plasmids for fast purification of the 
corresponding proteins. Red shadowed residues are those involved in the 
interaction between p53 and MDM2 or MDMX. 
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Figure II.2. SDS-PAGE of purified protein fragments and determination 
of molecular mass. 
 
 
Figure II.3. Identification of purified p53, MDM2, and MDMX 
protein fragments by dot blotting analysis. 3 ng (lane 1), 30 ng (lane 2) 
or 300 ng (lane 3) of p53, MDM2 or MDMX were spotted on a 
nitrocellulose filter previously activated in methanol. After the deposition 
the filter was incubated with the anti-p53 (A), anti-MDMX (B) or anti-
MDM2 (C) antibodies as reported in the 4.II.1 section. Filters were 
developed according to the chemio-luminescence method using the ECL 
kit purchased from Millipore. 
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Panel A 
 
Panel B 
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Figure II.4. MALDI-TOF spectra of purified MDM2 (Panel A), 
MDMX (Panel B) and p53 (Panel C). Mass spectrometry analysis of 
native proteins was performed with a MALDI–TOF micro MX 
(Waters Co., Manchester, UK), equipped with a pulsed nitrogen laser 
(k = 337 nm) as reported. 1µL of the prepared sample was placed on 
the mass spectrometer and analyzed. 
The molecular masses determined for the entire protein fragments 
expressed (15215, 12564 and 37125 for MDM2, MDMX and p53, 
respectively) were in good agreement with those derivable from the 
amino acid sequence of the corresponding protein (15182, 12617 and 
37193, respectively). 
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Table II.1.  Comparison between the molecular mass of p53, 
MDM2, and MDMX determined with different 
methods 
 
 SEQUENCES 
(Daltons) 
SDS-PAGE 
(Daltons) 
MALDI-TOF 
(Daltons) 
p53 37192.8 56260.3 37125.51 
MDM2 15182.3 21062.02 15215.41 
MDMX 12616.6 12201.13 12563.64 
 
 
II.4.b Electrophoresis mobility of p53, MDM2, and MDMX protein 
interacting fragments on native PAGE 
The interaction between the oncosuppressor p53 and its protein 
ligands has been studied on native PAGE. Under the experimental 
conditions reported above (Experimental section II.3.c), p53 did not enter 
the gel (Fig. II.5A, lane 1), and almost all the loaded protein remained in 
the well (not shown), a result confirming the property of p53 to form high 
molecular weight aggregates [Ishimaru et al., 2003]. On the other hand, 
both MDM2 (Fig. II.5A, lanes 2–5) and MDMX (Fig. II.5A, lanes 10–12) 
entered the gel and exhibited an electrophoresis mobility that was slightly 
lower for MDMX. The absence of staining material in the wells excluded 
the possibility that, under these conditions, insoluble aggregates of these 
two protein fragments were formed. It is to be pointed out that the 
stacking gel has to be omitted as MDM2 and MDMX stopped their 
migration at the interface between the two gels (not shown), a procedure 
already employed for studying the interaction between elongation factors 
and some of their interacting molecules [Krasny et al., 1998; Raimo et al., 
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2000; Masullo et al., 2000].  
A dose-dependent staining was observed for both MDM2 and 
MDMX, and the plot profile option of the ImageJ (Fig. II.5B) software 
allowed to derive a relationship between the intensity of the protein bands 
and their concentration (Fig. II.5, panel C). When p53 and MDM2 or 
MDMX were mixed together prior loading, a reduction of their signal in 
the corresponding migrating bands was observed (Fig. II.5A, lanes 6–9 
and 13–15 for MDM2 and MDMX, respectively), thus indicating that a 
stable complex was formed between the two protein fragments. However, 
under these conditions, at the highest concentration of MDM2 (lane 9) or 
MDMX (lane 15), the amount of p53 employed was not sufficient to 
bound all the MDM2/X used. This procedure was then used to study the 
interaction between p53 and MDM2 or MDMX protein fragments. In 
fact, as shown in Fig. II.6, the titration of a fixed amount of MDM2 (Fig. 
II.6A) or MDMX (Fig. II.6B) with increasing amounts of p53 led to the 
progressive diminution of the intensity of the protein band corresponding 
to MDM2 or MDMX. The densitometric analysis of protein bands was 
used for the construction of a dose–effect graph in which a typical 
saturation behaviour was found (Fig. II.6C). The analysis of the data, 
according to a hyperbolic equation, confirmed this hypothesis and 
permitted the extrapolation of the concentration of MDM2/MDMX 
required to bind half of the amount of p53 used in the assay. The obtained 
values (2.9 and 9.4 µM for MDM2 and MDMX, respectively), although 
higher than those determined using a biotinylated p53 peptide in a surface 
plasmon resonance experiment (0.8 and 2.2 µM, respectively) [Noguchi 
et al., 2013], confirmed the finding that the affinity for p53 is roughly 
three-fold higher for MDM2 than that for MDMX. 
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Figure II.5. Electrophoresis mobility of p53, MDM2, and MDMX 
protein interacting fragments on native PAGE. (A) Migration of p53, 
MDM2, and MDMX on a 12% w/v native polyacrylamide gel. A 22 µL 
mixture, prepared as reported in the text (Experimental section 3.II.3), 
contained 20.4 µM p53 (lane 1); 8.3, 16.6, 25.0, and 36.7 µM MDM2; or 
9.2, 18.4, and 33.8 µM MDMX in the absence (lanes 2–5 and 10–12, 
respectively) or presence (lanes 6–9 and 13–15, respectively) of 20.4 µM 
p53. The migration of MDM2 and MDMX is indicated with an arrow on 
the left. (B) Scanning densitometry of the migrating bands reported in 
(A). (C) Relationship between MDM2/MDMX fragment concentration 
and intensity signals. The data were derived from three to four different 
gels run and analysed as in (A) and (B), respectively. The significance of 
the correlation was evaluated using the statistical parameter t in a two-
tailed test with 19 and 12 degrees of freedom for MDM2 (filled circles) 
and MDMX (empty circles), respectively. 
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Figure II.6. Titration of MDM2/MDMX with p53. A total of 31.66 µM 
MDM2 (A) or 14.6 µM MDMX (B) was incubated in the absence (lanes 2 
and 10) or presence of 2.9, 5.7, 8.6, 11.4, 14.3, 17.2, and 20 µM p53 (the 
highest concentration run alone in lane 1) and analysed on a 12% w/v 
native polyacrylamide gel electrophoresis. The scanning densitometry of 
the protein band signals on three different gels carried out at different 
MDM2/MDMX concentration was then derived. The data were reported 
(C) as the ratio between the amount of unbound MDM2/X (lanes 3–9) 
and the total con- centration of MDM2/X used (lanes 2 and 10, 
respectively). Curve fitting was done using the hyperbolic function of the 
Kaleidagraph software (4.3.1 version). The significance of the correlation 
was evaluated using the statistical parameter t in a two-tailed test with 17 
and 13 degrees of freedom for MDM2 (filled circles) and MDMX (empty 
circles), respectively. 
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II.4.c Dissociative effect of Nutlin-3a, Nutlin-3b, andRO-5963 on the 
preformed p53·MDM2/X complex 
To study the dissociative effect of Nutlin-3a, Nutlin-3b, and RO-
5963 on the preformed p53·MDM2 complex, they were added to the 
reaction mixture. As reported in Fig. II.7, the addition of those inhibitors 
caused the dissociation of MDM2 from the complex (Fig. II.7A, B, and C, 
respectively). In addition, the amount of ligand released from the complex 
increased as the concentration of the dissociation agent increased. The 
densitometric evaluation of the released MDM2 allowed the 
determination of the concentration of inhibitor required to dissociate half 
the complex formed (IC50). In fact, either from the inflection point of a 
semi-logarithmic plot (Fig. II.7D) or from a saturation behaviour (Fig. 
II.7E), very similar values of the IC50 can be derived and averaged (Table 
II.2). Although the values obtained are higher than those determined 
using different methods [Vassilev et al., 2004; Graves et al., 2013], the 
method confirmed that Nutlin-3a showed a dissociative potency similar to 
RO-5963, but higher than that elicited by Nutlin-3b. 
The results shown in Fig. II.8 confirmed that the method is 
appropriate as well for the analysis of the p53·MDMX complex 
dissociation exerted by the above-mentioned inhibitors (Fig. II.8A, B and 
C, corresponding to Nutlin-3a, Nutlin-3b, and RO-5963 effect, 
respectively). In fact, either from a semi-logarithmic plot (Fig. II.8E) or 
from a titration behaviour (Fig. II.8F), the values of the IC50 can be 
derived and are reported in Table II.2. Also in this case, still remaining 
values of the IC50 higher than those reported [Graves et al., 2013], the 
results confirmed the specificity of RO-5963 toward the dissociation of 
MDMX from the complex. 
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An interesting finding emerged when the effect of the inhibitors 
on the electrophoretic behaviour of the MDM2 or MDMX alone, was 
considered. In fact, while Nutlin-3a and -3b did not influence the mobility 
of MDM2 and MDMX (not shown), RO-5963 reduced the mobility of 
MDMX (Fig. II.8D), but not that of MDM2. In addition, the effect was 
dose-dependent and, at intermediate concentration, both the fast and slow 
migrating MDMX bands can be detected in the gel (Fig. II.8D). This 
finding can be associated with the MDMX oligomerization induced by 
RO-5963, a behaviour demonstrated using different techniques [Graves et 
al., 2013]. The effect of RO-5963 on MDMX, was also analysed by gel-
filtration, and the results reported in Fig. II.9 confirmed that the inhibitor 
induced MDMX dimerization. Therefore, the slow (MDMX)2 homodimer 
migrating rate might indicate a more compact structure of the complex, 
possessing a lower charge/mass ratio. Also in this case, the densitometric 
analysis of the gel allowed the determination of the RO-5963 
concentration required to half oligomerizate the amount of the MDMX 
used, either from the fast migrating band disappearing, or from the slow 
migrating band appearing (Fig. II.8G). Being the obtained value (0.7 µM) 
identical to that measured for the dissociation of MDMX from a 
p53·MDMX complex, it can be inferred that the dimerization of MDMX 
is required to dissociate the complex, thus confirming the results obtained 
using a different and more complex methodology [Graves et al., 2013]. 
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Figure II.7. Dissociative effect of Nutlin3a, Nutlin3b, and RO5963 on 
the preformed p53·MDM2 complex. Representative electrophoresis 
polyacrylamide gels in nondenaturing conditions for the analysis of the 
dissociation power of the inhibitors tested. (A) The reaction mixture 
containing 25 µM p53·MDM2 complex, treated in the absence (lane 3) or 
in the presence (lanes 4–14) of 0.040, 0.060, 0.080, 0.12, 0.33, 0.67, 1.33, 
3.33, 6.67, 33.33, and 333.33 µM Nutlin-3a, respectively, were run on a 
12% nondenaturing polyacrylamide gel. 30 µM MDM2 and p53 was run 
alone in lanes 1 and 2, respectively. (B) As in (A), but using Nutlin-3b, at 
concentration of (lanes 4–14) of 1.33, 6.67, 13.33, 20.00, 66.67, 133.33, 
266.67, 333.33, 400.00, 833.33, and 1666.67 µM. p53 and MDM2 (25 
µM both) were run alone in lanes 1 and 2, respectively. (C) As in (A), but 
using RO-5963, at concentration of 0.10, 0.21, 0.42, 0.83, 1.67, 3.33, 
8.33, 16.67, 33.33, 166.67, and 333.33 µM (lanes 4–14), respectively. (D) 
The percentage of the residual p53·MDM2 complex was reported in a 
semilogarithmic plot, at the corresponding concentration of Nutlin-3a 
(empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), 
respectively. (E) The percentage of MDM2 dissociated from the complex 
was reported as a function of the inhibitor concentration. Curve fitting 
was done using the hyperbolic function. Symbols as in (D). 
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Figure II.8. Dissociative effect of Nutlin-3a, Nutlin-3b, and RO-5963 
on the preformed p53·MDMX complex. Representative electrophoresis 
polyacrylamide gels in nondenaturing conditions for the analysis of the 
dissociation power of the inhibitors tested. (A) The reaction mixture 
containing 18 µM p53·MDMX complex treated in the absence (lane 2) or 
in the presence (lanes 3–8) of 5, 10, 20, 50, 100, 200, 333, and 667 µM 
Nutlin-3a, respectively, was run on a 12% nondenaturing polyacrylamide 
gel. Eighteen micromolar MDMX was run alone in lane 1. (B) As in (A), 
using Nutlin-3b concentration of 0.133, 0.667, 0.400, 1.667, 3.333, and 5 
µM Nutlin-3b (lanes 3–8). The migration of the p53·MDMX complex or 
MDMX alone was analyzed in lanes 1 and 2, respectively. (C) As in (A), 
using 0.104, 0.208, 0.417, 0.833, 1.667, 3.333, and 10 µM RO-5963 
(lanes 3–8). The migration of MDMX alone or in complex with p53 was 
analyzed in lanes 1 and 2, respectively. (D) The migration of 20 µM 
MDMX treated in the absence (lane 1) or in the presence of 0.104, 0.208, 
0.417, 0.833, 1.667, and 3.333 µM RO-5963 (lanes 1–7) was analyzed. 
(E) The percentage of the residual p53·MDMX complex, was reported in 
a semilogarithmic plot, at the corresponding concentration of Nutlin-3a 
(empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), 
respectively. (F) The percentage of MDMX dissociated from the 
p53·MDMX complex was reported as a function of the inhibitor 
concentration. Curve fitting was done using the hyperbolic function. 
Symbols as in (E). (G) The percentage of slow (filled squares) and fast 
(empty squares) migrating MDMX species (D) were reported as a 
function of the RO-5963 concentration 
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Table II.2  Concentration of inhibitors leading to the 50% dissociation 
of the p53·MDM2/X complex 
Values in parentheses indicate the number of gels considered in the analysis. The 
statistical significance was evaluated in a t-Student test; in each cases p < 0.005. 
  
 
Inhibitor Nutlin-3a Nutlin-3b RO-5963 
 IC50 (µM) Range (µM) IC50 (µM) Range (µM) IC50 (µM) Range (µM) 
MDM2 1.8 ± 0.8 (8) 0.04 - 333 99.1 ± 32.9 (8) 1.3 - 1667 0.7 ± 0.1 (4) 0.1 - 3.3 
MDMX 67.5 ± 3.9 (4) 5 - 666 270.9 ± 47.0 (4) 133 - 1667 0.7 ± 0.2 (12) 0.1 - 3.3 
Values in parentheses indicate the nu ber of gels considered in the analysis. The 
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Figure II.9 Analysis on gel-filtration. The effect of RO-5963 on 
oligomerisation state of MDMX was analyzed by gel-filtration on a 
SuperdexTM 75 10/300 GL column (GE Healthcare) connected to an 
FPLCTM system. The column was equilibrated at 0.5 mL/min at room 
temperature (20 – 24°C) with a 20 mM Tris•HCl buffer, pH 7.8, 
containing 100 mM NaCl, and calibrated with Carbonic Anhydrase (30 
kDa), Cytochrome C, (12.4 kDa) (whose elution position was indicated 
on the top of Panel A), and Ovoalbumin (46 kDa) as protein molecular 
mass standards. 500–µL fractions were collected, and the protein content 
was analyzed by 12% SDS-Page. (A) 200–µL (8.4 µM) purified MDMX 
was analyzed after a 20 min treatment at 37°C in the absence (dashed 
line), or in the presence of 3.6 µM RO-5963 (continuous line). Both 
samples eluted as a single peak accounting for molecular masses of 13 
kDa and 24 kDa, for the untreated and RO-5963 treated samples, thus 
confirming that RO-5963 induced MDMX homodimerisation. (B) SDS-
Page of the indicated fractions (20 µL) collected from the analysis of the 
RO-5963 untreated sample. (C) SDS-Page of the indicated fractions (20 
µL) collected from the analysis of the RO-5963 treated sample. 
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Conclusions 
 
The research work carried out in this PhD thesis is focused on the 
adaptation of common and simple biochemical techniques in order to 
study the protein-ligand interactions involved in some frequent incidence 
diseases, such as Alzheimer's disease and cancer. For both topics, a 
multidisciplinary approach, including pharmacology, bio-informatics, 
organic chemistry, molecular biology, and of course biochemistry, has 
been applied. 
Although protein-ligand interaction can be studied with a large 
variety of biophysical techniques, in this thesis two different 
methodologies were used. From one hand, a molecular enzymology 
approach allowed the study of the inhibition power exerted by new 
synthesized donepezil analogues to be used as lead compound for the 
development of new pharmacological agents for the treatment of 
Alzheimer's disease. On the other hand, electrophoresis under not 
denaturing conditions has been used to develop a new analytical method 
for the characterisation of the interaction between the oncosuppressor p53 
and its protein ligands MDM2 and MDMX, as well as the dissociation of 
the respective complexes. 
 Regarding the treatment of AD, the enzymatic inhibition tests on 
AChE and BuChE have been realized on all the synthetized substrate 
analogues in order to study the influence of the characteristic unsaturation 
between the two moieties on the Donepezil activity and selectivity. 
Moreover, a demethylation step was conducted on a set of selected 
substrates in order to study the role of methoxyl group. All the 
synthetized derivatives were less active than Donepezil and did not 
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influenced the cell viability in SH-SY5Y neuroblastoma cells. No 
improvement in the inhibitor activity was observed with the introduction 
of hydroxyl groups on the molecules, whereas the substitution of a 
stereocenter with a double bond, even reducing the inhibition activity on 
AChE compared to Donepezil, open the possibility to exploit such 
synthetically simplified Donepezil analogues as better inhibitors of 
BACE-1. Indeed, compounds GP9 and GP10, considering their 
selectivity for cholinesterase inhibition and their effect on BACE-1 
activity, could represent promising candidates for the development of 
drugs with dual inhibitor activity for AD treatment. 
Regarding the study of the association between the interacting 
domain of p53 and its protein partners MDM2 and MDMX, it is 
important to remind that the activation of p53 tumor suppressor by 
antagonizing its negative regulators MDM2/X has been considered an 
attractive strategy for cancer therapy. Great effort has been given in the 
development of drugs able to dissociate the p53·MDM2/X complex. 
Under this regard, the polyacrylamide gel under native conditions can be 
useful to easily discriminate, among library of compounds with 
pharmacological activity against cancer development, the molecules with 
a remarkable dissociative potency, preventing the use of expensive and 
more sophisticated technology, as NMR technology [Daniele et al., 2014; 
D’Silva et al., 2005], surface plasmon resonance [Noguchi et al., 2013], 
or fluorescence polarization [Reed et al., 2010; Zhang et al., 2013]. The 
relevance in applying Native-PAGE resides in the fact that it is much 
simpler and did not require any tagging/derivatization procedure of the 
protein fragments employed. 
Conclusions 
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Although both research projects deserve further studies, the results 
here presented are useful for several purposes. Concerning the donepezil-
like compounds, a design of new inhibitors will be considered, in 
particular with the aim to develop drugs endowed with a dual inhibitory 
effect, like that one observed for GP9 and GP10 compounds. Finally, 
concerning the gel-shift technique applied to investigate on p53-
MDM2/X complex, we will work for a routinely application of this 
method to quickly analyze new compounds as potential dissociator 
agents, making even more inexpensive the first screening of molecular 
libraries, a necessary approach to identify new pharmaceuticals.  
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